Quantitative Pharmacology Overview

Principles

Definition

Quantitative pharmacology is the scientific discipline that employs mathematical modeling, statistics, and simulation to characterize, understand, and predict the pharmacokinetic and pharmacodynamic properties of drugs and their effects in biological systems. This quantitative approach is essential for optimizing drug dosing, evaluating efficacy and safety, and guiding rational drug development throughout the drug lifecycle.

Ontological type

Core Methods

Drug Development Applications

Modeling Frameworks

Key developments

Key Figures

Foundational PK/PD Paradigm era

David Rodbard [1], linked with the Massachusetts Institute of Technology [3] and Johns Hopkins University [4] in this era, helped shape the quantitative pharmacology foundation. His contribution, as described in the 1974 Statistical Quality Control and Routine Data Processing for Radioimmunoassays and Immunoradiometric Assays [7], advanced statistical quality control and routine data processing, underpinning reproducibility and enabling model-based dose optimization in clinical monitoring. Corwin Hansch [2], affiliated with the University of California, San Francisco [5] and the University of Colorado Denver [6] during this era, helped anchor the era’s structure–activity thinking. His 1968 study on the parabolic dependence of drug action upon lipophilic character [8] highlighted how lipophilicity shapes drug effects, reinforcing lipophilicity-driven medicinal chemistry and early structure–activity principles.

Model-driven Drug Development era

Richard A. Friesner[1] is a pivotal figure in the Model-driven Drug Development era, with affiliations at Massachusetts Institute of Technology[3] and University of California, San Francisco[4]. His key contributions center on Glide, a rapid docking and scoring approach described in Glide: A New Approach for Rapid, Accurate Docking and Scoring[7], which enabled high-throughput virtual screening and enrichment-based database screening to guide lead optimization and translational decisions. Paola Gramatica[2] is associated with Umeå University[5] and University of British Columbia[6] during this era. Her contributions include Principles of QSAR models validation: internal and external[8], providing a formal framework for QSAR model validation that underpins regulatory acceptance and model-based decision making in this era.

Integrated Systems Pharmacology era

Yun Tang [1], associated with East China University of Science and Technology [3] and Carnegie Mellon University [4], emerges as a leading figure in Integrated Systems Pharmacology during this era. Tang's key contributions in this era include the 2012 paper 'Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference' [7], which proposed network-based inference to predict drug-target interactions and reposition existing drugs, thereby enabling scalable, network-informed pharmacology foundational to precision dosing. Weihua Li [2], affiliated with University of Pennsylvania [5] and Washington University in St. Louis [6], co-authored the 2012 paper 'Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference' [7]. These contributions to network-based inference [7] helped integrate mechanistic models with omics data, underpinning translational QS frameworks that support regulatory use and clinical decision support.